Volanesorsen and triglyceride levels in familial chylomicronemia syndrome
New England Journal of Medicine Aug 13, 2019
Witztum JL, Gaudet D, Freedman SD, et al. - Researchers evaluated the safety and efficacy of volanesorsen in a phase 3, double-blind, randomized, 52-week trial. The study sample consisted of 66 patients with familial chylomicronemia syndrome who were randomized in a 1:1 ratio to receive volanesorsen or placebo. Volanesorsen treatment reduced triglyceride levels to < 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Adverse events commonly encountered included thrombocytopenia and injection-site reactions.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
Sign up with M3 India to try daily quizzes and take part in competitionsTry M3 India / Log In
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor